Pharmacological and Formulation Advances in the Management of Hepatic and Inflammatory Disorders: A Review of Acalypha Fruticosa and Tribulus Terrestris

Background: The increasing global burden of liver diseases and chronic inflammatory conditions necessitates the exploration of effective, plant-based therapeutics. Acalypha fruticosa and Tribulus terrestris are two medicinal plants deeply rooted in traditional ethnomedicine, widely recognized for their diverse biological activities. Objective: To systematically review the current literature surrounding Acalypha fruticosa and Tribulus terrestris, focusing on their antioxidant, anti-inflammatory, and hepatoprotective mechanisms, and to explore recent advances in standardizing these extracts into modern pharmaceutical dosage forms. Methods: A comprehensive review of recent literature was conducted. In vitro, in vivo, and formulation studies evaluating the phytochemical composition, metabolic modulation, and drug delivery systems of both plant extracts were analyzed. Discussion: Pharmacological evaluations confirm that Acalypha fruticosa possesses potent antioxidant and anti-inflammatory properties, driven by compounds like acalyphin that activate PPAR receptors and inhibit NF-κB pathways. Concurrently, Tribulus terrestris demonstrates profound hepatoprotective effects by neutralizing oxidative stress and restoring endogenous antioxidant enzymes. Furthermore, recent pharmaceutical advancements have successfully standardized these hygroscopic extracts into modern dosage forms, including tablets, capsules, and effervescent formulations, significantly enhancing patient compliance and bioavailability. Conclusion: The literature robustly validates the pharmacological efficacies of A. fruticosa and T. terrestris. Their complementary mechanisms of action—coupled with modern formulation technologies—highlight their significant potential for integration into advanced therapeutic regimens for liver and inflammatory disorders.